AMT could stop ulceration

Article

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Amniotic membrane transplantation (AMT) may stop corneal ulceration and promote epithelialization, according to an investigation.

Dr Stanislav A. Iakimenko et al., Department of Eye Burns, Ophthalmic Plastic Surgery, Keratoplasty and Keratoprosthesis, State Institution,The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Ukraine, analysed the results of 55 AMTs in 53 eyes of 53 patients.

All patients had corneal ulceration and limbal deficiency 180-360° of the limbus after grade 4-6 chemical and thermal injuries was performed. The preoperative visual acuity (VA) was

The findings showed that corneal ulceration was prevented in 98.1% of cases and corneas were epithelialized in 76.3% of AMTs. Corneal defect recurred in 7.1% of successful cases and VA was ≥0.01 in 54.8% of patients after corneal epithelialization.

VA at the last follow-up visit improved on 2 or more lines on the eye chart, compared to preoperative VA in 35.7% with corneal epithelialization. VA didn’t improve in 42.9% of successful patients and it reduced by one line in 26.2% of patients.

Please visit the latest online issue of the European Journal of Ophthalmology to see the abstract.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.